Dr. Salles on New Agents Being Investigated in Follicular Lymphoma

Gilles Salles MD, PhD
Published: Monday, Apr 10, 2017



Gilles Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being investigated for patients with follicular lymphoma.

PI3 kinase inhibitors are currently of interest in patients with follicular lymphoma who have failed prior therapy. A select group of patients will benefit from these drugs and the response generally lasts for 1 year.

A small portion of patients respond to BTK inhibitors, such as ibrutinib (Imbruvica), but only some of the responses are long lasting, explains Salles.

Additionally, immunotherapy has not had much activity as a single agent, but combinations are currently being investigated for patients with follicular lymphoma.
 


Gilles Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being investigated for patients with follicular lymphoma.

PI3 kinase inhibitors are currently of interest in patients with follicular lymphoma who have failed prior therapy. A select group of patients will benefit from these drugs and the response generally lasts for 1 year.

A small portion of patients respond to BTK inhibitors, such as ibrutinib (Imbruvica), but only some of the responses are long lasting, explains Salles.

Additionally, immunotherapy has not had much activity as a single agent, but combinations are currently being investigated for patients with follicular lymphoma.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x